All In Biotech

Drug Trial Radar · NCT06304961

A Study to Investigate Relative Bioavailability of Two Different Dosage Forms for Tozorakimab Via Subcutaneous Administration in Healthy Volunteers

A Randomised, Single-dose, Parallel Group Study in Healthy Volunteers to Assess the Relative Bioavailability of Two Different Dosage Forms for Tozorakimab Via Subcutaneous Administration

Last checked: Nov 20, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

46

Actual

Start

Apr 8, 2024

Primary completion

Sep 9, 2024

Study completion Sep 9, 2024

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Mar 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study will assess the relative bioavailability between two dosage forms of tozorakimab (test dosage form and reference dosage form) and to assess the pharmacokinetic (PK) profiles of both dosage forms.

Conditions

  • Healthy Participants

Interventions

  • TozorakimabBiological

    Tozorakimab will be administered as a single SC dose on Day 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the concentration-time curve from time 0 to infinity (AUCinf)Time frame: Day 1 (Pre-dose), Days 3, 4, 5, 7, 8, 9, 15, 29, 43, 57, 85 and 113 (Post-dose).
  2. Area under the concentration-curve from time 0 to the last quantifiable concentration (AUClast)Time frame: Day 1 (Pre-dose), Days 3, 4, 5, 7, 8, 9, 15, 29, 43, 57, 85 and 113 (Post-dose).
  3. Maximum observed drug concentration (Cmax)Time frame: Day 1 (Pre-dose), Days 3, 4, 5, 7, 8, 9, 15, 29, 43, 57, 85 and 113 (Post-dose).

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Berlin, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.